Posts

Inhibrx's OX40 Agonist INBRX-106 Doubles Tumor Response Rate with Keytruda in Head and Neck Cancer Trial

on
Inhibrx's phase 2 HexAgon study in treatment-naïve, high PD-L1 (CPS ≥20) metastatic HNSCC patients showed 44% ORR with INBRX-106 + Keytruda vs 21.4% with Keytruda alone. Combination arm had three complete responses and majority of responders with >50% tumor shrinkage. ORR aligns with Merck's phase 3 Keytruda monotherapy data (23.3%) in similar population. INBRX-106 attracted M&A interest from Merck & Co. and others, potentially valued over $8B. Progression-free survival data expected Q4; trial modeled on Merck's design for clear signal. Sources:

Argenx's Vyvgart and Vyvgart Hytrulo Receive FDA Label Expansion for All Adult gMG Patients

on

Astellas Highlights Positive Early Data from Stem Cell-Derived RPE Therapy for Geographic Atrophy

on

Capricor Sues Nippon Shinyaku and NS Pharma Over Pricing Flaw and Launch Delays for Deramiocel DMD Therapy

on

Trump Reportedly Planning to Fire FDA Commissioner Marty Makary

on

FDA Approves Bizengri (Zenocutuzumab) for NRG1 Fusion-Positive Cholangiocarcinoma, First Targeted Therapy for Ultra-Rare Bile Duct Cancer

on

Access to Apps Reshaping Healthcare in Shandong

on

Why AI's Top Young Talent Isn't Interested in Careers at Big Drugmakers

on

Daiichi Sankyo's ADC Manufacturing Investments and Market Position

on

Odyssey Therapeutics Secures $279M IPO Amid Biotech Funding Challenges

on

FDA Extends Review of LEQEMBI IQLIK Subcutaneous Starting Dose for Early Alzheimer's Disease

on

Angelini Fortifies Neurology Portfolio with $4.1B Buyout of Catalyst

on

Atara and Pierre Fabre Secure FDA Type A Meeting for Ebvallo After Second CRL, Amid Leadership Shifts

on